Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beam Therapeutics, Inc.

27.25
+1.144.37%
Post-market: 27.380.1300+0.48%17:56 EST
Volume:1.39M
Turnover:36.90M
Market Cap:2.21B
PE:-5.95
High:27.50
Open:25.31
Low:24.52
Close:26.11
Loading ...

Stock Track | Beam Therapeutics Soars on Promising Sickle Cell Therapy Data

Stock Track
·
06 Nov 2024

Scotiabank Remains a Hold on Beam Therapeutics (BEAM)

TIPRANKS
·
06 Nov 2024

Beam Therapeutics Raised to Outperform From Market Perform by Leerink Partners

Dow Jones
·
06 Nov 2024

RBC Capital Remains a Hold on Beam Therapeutics (BEAM)

TIPRANKS
·
06 Nov 2024

Stock Track | Beam Therapeutics Soars on Promising Sickle Cell Therapy Data

Stock Track
·
06 Nov 2024

Leerink Partners Upgrades Beam Therapeutics to Outperform From Market Perform, Adjusts PT to $39 From $27

MT Newswires Live
·
06 Nov 2024

Beam Therapeutics Inc : Leerink Partners Raises to Outperform From Market Perform; Raises Target Price to $39 From $27

THOMSON REUTERS
·
06 Nov 2024

Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: Promising BEACON Trial Results ...

GuruFocus.com
·
06 Nov 2024

Q3 2024 Beam Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
06 Nov 2024

Beam Therapeutics Reports Steady Progress in Q3 2024

TIPRANKS
·
06 Nov 2024

Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial

Benzinga
·
06 Nov 2024

Beam could see significant upside over next 6-12 months, says Wedbush

TIPRANKS
·
06 Nov 2024

BUZZ-Beam Therapeutics falls after patient death in early trial

Reuters
·
05 Nov 2024

Buy Rating Affirmed for Beam Therapeutics Due to Promising BEAM-101 Developments in Sickle Cell Disease Treatment

TIPRANKS
·
05 Nov 2024

Beam says patient death determined by investigator to be unrelated to BEAM-101

TIPRANKS
·
05 Nov 2024

Beam Therapeutics to present data on BEAM-101, BEAM-201 at ASH meeting

TIPRANKS
·
05 Nov 2024